Annals of Oncology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis.
33:S591-S592.
2022
-
138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial.
33:S602-S602.
2022
-
633P Determining the prognostic value of end of treatment (EOT) 18F-choline positron emission tomography (PET) in patients treated with primary central nervous system lymphoma (PCNSL) who respond to first-line therapy: A single centre retrospective study at the Royal Marsden Hospital (RMH).
33:S832-S832.
2022
-
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.
32:896-905.
2021
-
A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.
31:951-957.
2020
-
Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study.
30:ix1-ix1.
2019
-
Corrections to “De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017”.
30:1181-1181.
2019
-
A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases.
30:iii73-iii73.
2019
-
Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
29:2153-2153.
2018
-
Influenza vaccine effectiveness among cancer patients: A population-based study using health administrative and laboratory testing data from Ontario, Canada.
29:viii568-viii568.
2018
-
Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database.
29:viii238-viii238.
2018
-
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.
29:1423-1430.
2018
-
Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al..
29:281-282.
2018
-
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC).
28:v314-v315.
2017
-
Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database.
28:v238-v238.
2017
-
Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26.
28:v398-v398.
2017
-
Development of a web-based application using machine learning algorithms to facilitate systematic literature reviews.
28:v518-v518.
2017
-
Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population.
28:v308-v309.
2017
-
Stereotactic ablative radiotherapy (SABR) for oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) during abiraterone therapy: A phase I study.
28:v292-v292.
2017
-
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
28:1700-1712.
2017
-
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.
28:1560-1568.
2017
-
Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.
28:1448-1456.
2017
-
A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer.
28:i4-i5.
2017
-
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
27:2216-2224.
2016
-
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers.
27:vi499-vi499.
2016
-
Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study.
27:1761-1767.
2016
-
Correction to: Planning and reporting of quality-of-life outcomes in cancer trials.
27:209-209.
2016
-
Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies.
26:2257-2266.
2015
-
Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis.
26:vi55-vi55.
2015
-
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
26:1533-1546.
2015
-
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis.
26:1305-1313.
2015
-
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200.
26:973-981.
2015
-
Planning and reporting of quality-of-life outcomes in cancer trials.
26:1966-1973.
2015
-
Cognitive function and fatigue after diagnosis of colorectal cancer.
25:2404-2412.
2014
-
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2.
25:2357-2362.
2014
-
Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer.
25:2096-2096.
2014
-
Angiogenic Switch As Predictor of Response to Chemotherapy+ Bevacizumab in Patients with Metastatic Colorectal Cancer.
25:iv181-iv181.
2014
-
Outcomes with Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma (Uc) Following Previous Perioperative Cisplatin-Based Therapy.
25:iv302-iv302.
2014
-
Phase 3 (P04832) Trial Results for Rolapitant, a Novel Nk-1 Receptor Antagonist, in the Prevention of Chemotherapy-Induced Nausea and Vomiting (Cinv) in Patients Receiving Cisplatin-Based Chemotherapy.
25:v1-v1.
2014
-
Phase Ii Study of Individualized Sunitinib As First-Line Therapy for Metastatic Clear Cell Renal Cell Cancer (Mrcc).
25:iv292-iv292.
2014
-
Reasons for Delay in Time to Initiation of Adjuvant Chemotherapy for Colon Cancer: a Multi-Institution Study.
25:iv198-iv198.
2014
-
The Significance of Complete Response (Cr) in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma (Uc).
25:iv301-iv301.
2014
-
Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy.
25:992-998.
2014
-
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.
25:763-773.
2014
-
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
25:808-815.
2014
-
Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice.
25:791-800.
2014
-
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
24:3065-3069.
2013
-
Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
24:3082-3088.
2013
-
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.
24:2972-2977.
2013
-
Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer.
24:2534-2542.
2013
-
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
24:2206-2223.
2013
-
Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC).
24:1986-1993.
2013
-
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
24:1792-1801.
2013
-
Adolescents with acute lymphoblastic leukemia treated at pediatric versus adult hospitals.
24:801-806.
2013
-
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
24:355-361.
2013
-
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole..
24:355-361.
2013
-
Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods.
23:2977-2982.
2012
-
Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods..
23:2977-2982.
2012
-
Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer.
23:ix297-ix298.
2012
-
Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor.
23:ix265-ix266.
2012
-
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.
23:1780-1788.
2012
-
Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials.
23:1633-1639.
2012
-
P-0215 Patient Factors Involved in Referral for Lynch Syndrome.
23:iv91-iv91.
2012
-
P1.20 CDX2 VDR Polymorphism Impinges on the Response of Cultured Breast Cancer Cell Lines to Vitamin D.
23:v17-v18.
2012
-
P1.26 Micrornas' Expression Profile and their Correlation with Clinical Outcome in head and Neck Squamous Cell Carcinoma.
23:v19-v20.
2012
-
P3.10 Microrna Profiling in Gastric Cancer.
23:v35-v36.
2012
-
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.
23:1512-1517.
2012
-
Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points.
23:1646-1651.
2012
-
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
23:1185-1189.
2012
-
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial..
23:1185-1189.
2012
-
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).
23:238-244.
2012
-
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)..
23:238-244.
2012
-
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?.
22:2387-2393.
2011
-
Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis.
22:2358-2365.
2011
-
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
22:2417-2423.
2011
-
Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial.
22:2086-2093.
2011
-
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma.
22:910-915.
2011
-
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients.
22:595-602.
2011
-
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
21:2220-2226.
2010
-
Activity of fulvestrant in HER2-overexpressing advanced breast cancer.
21:1246-1253.
2010
-
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12).
21:283-290.
2010
-
Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials.
21:19-26.
2010
-
Stopping a trial early in oncology: for patients or for industry?.
20:395-396.
2009
-
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
19:1749-1753.
2008
-
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
19:877-882.
2008
-
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
19:746-751.
2008
-
A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes.
18:1646-1651.
2007
-
Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma.
18:1680-1684.
2007
-
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
18:1177-1184.
2007
-
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.
18:116-121.
2007
-
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials.
17:1749-1760.
2006
-
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
17:1637-1643.
2006
-
Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing.
17:1090-1095.
2006
-
Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?.
17:1035-1036.
2006
-
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG).
17:952-956.
2006
-
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
17:334-340.
2006
-
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005.
16:1569-1583.
2005
-
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
16:1688-1694.
2005
-
Communicating prognosis in cancer care: a systematic review of the literature.
16:1005-1053.
2005
-
Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
16:735-742.
2005
-
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
16:716-725.
2005
-
The difference between study recommendations, stated policy, and actual practice in a clinical trial.
15:1267-1273.
2004
-
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
15:770-774.
2004
-
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers.
15:665-670.
2004
-
Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
14:1762-1767.
2003
-
ESMO takes a stand on supportive and palliative care.
14:1335-1337.
2003
-
Mammographic screening: case–control studies.
14:1190-1192.
2003
-
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer.
14:1017-1025.
2003
-
DNA methyltransferase inhibitors—state of the art.
13:1699-1716.
2002
-
Hormonal replacement therapy in breast cancer.
13:73-80.
2002
-
Critical appraisal of the Minimal Clinical Recommendations (MCR) of the European Society for Medical Oncology (ESMO): challenges for a European framework for the development of clinical practice guidelines.
13:1507-1508.
2002
-
Informing breast cancer patients about clinical trials:a randomized clinical trial of an educational booklet.
13:1414-1423.
2002
-
Malignant pleural mesothelioma: a phase II trial with docetaxel.
13:412-415.
2002
-
Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncologyclinic.
13:12-15.
2002
-
A National Cancer Institute of Canada Clinical Trials Group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
12:919-922.
2001
-
A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer.
12:773-778.
2001
-
The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives.
12:301-310.
2001
-
A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours.
11:1579-1584.
2000
-
Attitudes towards and participation in randomised clinical trials in oncology: A review of the literature.
11:939-946.
2000
-
Searching the medical literature for the best evidence to solve clinical questions.
9:377-383.
1998
-
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma.
9:217-219.
1998
-
Subcutaneous clodronate: A study evaluating efficacy in hypercalcemia of malignancy and local toxicity.
8:915-916.
1997
-
Radiation therapy following breast conservation surgery: Can it ever be avoided?.
8:217-218.
1997
-
On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993.
7:189-195.
1996
-
Phase II study of subcutaneous rHu-interleukin-2 and rHu-interferon α-2a in previously treated patients with multiple myeloma.
6:721-723.
1995
-
Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: A National Cancer Institute of Canada Clinical Trials Group Study.
3:201-204.
1992
-
A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.
2:681-686.
1991
-
The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)
2022
-
1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)
2022
-
1748P 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC)
2022
-
196P An international consensus on actions to improve lung cancer survival: A clinical review by the international cancer benchmarking partnership (ICBP)
2022
-
114TiP KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)
2021
-
5P Uncovering the evolution of glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers
2020
-
1195P The value of detecting resistance through liquid biopsy
2020
-
1816MO ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of carboplatin-based chemotherapy – with a focus on nausea. MASCC Antiemetic Study Group survey
2020
-
919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
2020
-
Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
2019
-
Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
2019
-
CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)
2019
-
CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)
2019
-
Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG)
2019
-
Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC)
2019
-
Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC)
2019
-
Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
2019
-
Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND226 study of durvalumab +/- tremelimumab in combination with platinum-doublet chemotherapy
2019
-
Prescription and treatment patterns of lenvatinib (L) in patients with radioactive iodine-refractory differentiated thyroid cancer (rDTC): A retrospective analysis of the Canadian Patient Support Program (PSP)
2019
-
Prescription and treatment patterns of lenvatinib (L) in patients with radioactive iodine-refractory differentiated thyroid cancer (rDTC): A retrospective analysis of the Canadian Patient Support Program (PSP)
2019
-
A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases
2019
-
Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice
2019
-
A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)
2018
-
Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)
2018
-
How advanced lung cancer patients are really treated at the population level? The Ontario, Canada experience
2018
-
The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review
2018
-
Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)
2017
-
Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26
2017
-
Feasibility of routine collection of health state utilities using EQ-5D in a breast cancer outpatient clinic
2017
-
Increasing palliative interventions at the end of life: patterns in metastatic colorectal cancer (mCRC)
2017
-
Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)
2017
-
Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)
2017
-
Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population
2017
-
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data
2017
-
Stereotactic ablative radiotherapy (SABR) for oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) during abiraterone therapy: A phase I study
2017
-
A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer
2017
-
A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)
2016
-
Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial
2016
-
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers
2016
-
Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)
2016
-
Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)
2016
-
NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
2016
-
Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis
2016
-
Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC)
2016
-
Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) – a validation study
2016
-
Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada
2016
-
Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience
2016
-
Safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving breast cancer resistant protein (BCRP) substrate chemotherapy agents
2016
-
genitourinary tumours, prostate Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)
2016
-
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
2016
-
Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis
2015
-
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
2015
-
Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc)
2014
-
Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc)
2014
-
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
2013
-
A PHASE I STUDY OF THE COMBINATION OF RO4929097 (RO) AND CEDIRANIB (CD) IN PATIENTS WITH ADVANCED SOLID TUMORS (PJC-004/NCI 8503)
2012
-
A PHASE IB COMBINATION STUDY OF RO4929097 (RO), A GAMMA-SECRETASE INHIBITOR, AND TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
2012
-
A Phase I Study of the Combination of RO4929097 (RO) And Cediranib (CD) in Patients with Advanced Solid Tumors (PJC-004/NCI 8503)
2012
-
A Phase IB Combination Study of RO4929097 (RO), A Gamma-Secretase Inhibitor, and Temsirolimus (TEM) in Patients (PTS) with Advanced Solid Tumors
2012
-
A RANDOMIZED PHASE II STUDY OF OGX-427 PLUS PREDNISONE (P) VS. P ALONE IN PATIENTS (PTS) WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)
2012
-
A Randomized Phase II Study of OGX-427 Plus Prednisone (P) Vs. P Alone in Patients (PTS) with Metastatic Castration Resistant Prostate Cancer (CRPC)
2012
-
ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
2012
-
EFFICACY AND SAFETY OF EVEROLIMUS IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER (BOLERO-2): EFFECT OF VISCERAL METASTASES AND PRIOR ENDOCRINE THERAPY
2012
-
LONG-TERM EFFICACY AND SAFETY OF L-BLP25 VACCINE IN A MULTI-CENTRE OPEN-LABEL STUDY OF PATIENTS WITH UNRESECTABLE STAGE III NSCLC
2012
-
MIR-99A/LET7C/MIR-125B SIGNATURE TO PREDICT SENSITIVITY TO ANTI-EGFR MONOCLONAL ANTIBODIES IN METASTATIC COLORECTAL CANCER (MCRC)
2012
-
PROGNOSTIC STRATIFICATION OF ADVANCED UROTHELIAL CARCINOMA (UC) RECEIVING SECOND-LINE SYSTEMIC THERAPY INCLUDING TIME FROM PRIOR CHEMOTHERAPY (TFPC) AS A PROGNOSTIC FACTOR
2012
-
SAFETY OF EVEROLIMUS FOR WOMEN OVER 65 YEARS OF AGE WITH ADVANCED BREAST CANCER: 18-MO FOLLOW-UP OF BOLERO-2
2012
-
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC
2012
-
CDX2 VDR POLYMORPHISM IMPINGES ON THE RESPONSE OF CULTURED BREAST CANCER CELL LINES TO VITAMIN D
2012
-
LUNG TUMORS TO BRAIN METASTASES: DO MICRORNAS PLAY A PROGNOSTIC ROLE?
2012
-
MICRORNA PROFILING AS A POTENTIAL PREDICTIVE TOOL OF GIANT CELL TUMOR EVOLVING IN HIGH GRADE OSTEOSARCOMA: A CASE REPORT
2012
-
MICRORNA PROFILING IN GASTRIC CANCER
2012
-
PATIENT FACTORS INVOLVED IN REFERRAL FOR LYNCH SYNDROME
2012
-
SUBCUTANEOUS ADMINISTRATION OF A THROMBOSPONDIN-1 MIMETIC PEPTIDE NORMALIZES TUMOR VASCULATURE, INCREASES DRUG UPTAKE AND INDUCES REGRESSION OF ADVANCED OVARIAN CANCER
2012
-
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
2012
-
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.
2012
-
AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR TRANSFORMED INDOLENT NON-HODGKIN LYMPHOMA: A REPORT OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP (CBMTG)
2011
-
IMPROVED 6-MONTH SURVIVAL RATE IN SUBJECTS WITH PROSTATE STEM CELL ANTIGEN POSITIVE TUMORS IN A GLOBAL, RANDOMIZED PHASE 2 TRIAL COMPARING GEMCITABINE VS. GEMCITABINE + AGS-1C4D4 (ASP6182) IN METASTATIC PANCREATIC CANCER
2011
-
A SYSTEMATIC REVIEW AND CONSENSUS RECOMMENDATIONS ON THE USE OF BIOMARKERS IN THE TREATMENT OF NON-SMALL CELL LUNG CARCINOMA (NSCLC)
2010
-
HIGH INCONSISTENCIES AMONG LISTS OF CAUTIONED and PROHIBITED DRUGS IN ONCOLOGY PHASE 1 AND PHASE 2 TRIALS
2010
-
INITIAL OUTCOME DATA FROM SCOTTISH BOWEL SCREENING PROGRAMME
2010
-
CISPLATIN DOSE INTENSITY CORRELATES WITH OUTCOME IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA RECEIVING CONCURRENT CISPLATIN BASED CHEMORADIATION: A MULTI-INSTITUTIONAL EXPERIENCE
2009
-
A PHASE 2 STUDY OF PATUPILONE IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (HRPC) WHO HAVE PROGRESSED AFTER DOCETAXEL
2008
-
EFFECTS OF ZOLEDRONIC ACID (ZOL) ON SURVIVAL IN PATIENTS WITH METASTATIC BONE DISEASE AND HIGH BONE TURNOVER: RESULTS FROM A META-ANALYSIS
2008
-
RANDOMIZED, DOUBLE-BLIND PHASE II TRIAL OF CARBOPLATIN plus PACLITAXEL [C plus P] WITH EITHER DAILY ORAL CEDIRANIB, AN INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR [VEGFR] TYROSINE KINASES, OR PLACEBO, IN ADVANCED NON-SMALL CELL LUNG CANCER [NSCLC]: A STUDY OF THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP
2008
-
RISK FACTORS FOR SKELETAL-RELATED EVENT (SRES) IN ZOLEDRONIC ACID-TREATED PATIENTS WITH BONE METASTASES (METS) FROM NON-SMALL CELL LUNG CANCER (NSCLC)
2008
-
THE PROGNOSTIC VALUE OF PAIN SCORES FOR CLINICAL OUTCOMES IN ADVANCED BREAST CANCER (BC), PROSTATE CANCER (PC), AND OTHER SOLID TUMORS (OST)
2008
-
Prognostic factors in advanced-stage pediatric anaplastic large cell lymphoma (ALCL): Analysis of patients from two consecutive pediatric oncology group (POG) studies
2008
-
Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006
2008
-
Phase II pilot study on brachytherapy with ECF vs brachytherapy and standard chemoradiation in esophageal cancer
2007
-
A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS
2006
-
A multicenter phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT)
2006
-
A phase II study of ispinesib in patients (PTS) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC)
2006
-
Mechanisms of cognitive function and fatigue: A prospective, longitudinal cohort study in colorectal cancer patients
2006
-
Phase I clinical trials referrals and enrollment: Five-year experience at the Princess Margaret Hospital
2006
-
Phase II study of bay 43-9006 (SORAFENIB) in patients with chemo-naive hormone refractory prostate cancer (HRPC)
2006
-
Prognostic significance of persistently elevated N-telopeptide levels in patients with bone metastases from solid tumors
2006
-
The role of patient values in evidence-based medicine (EBM) and its application to treatment decision-making between oncologists and women with breast cancer
2006
-
Zoledronic acid may improve survival in lung cancer patients with high baseline bone marker levels
2006
-
A phase II trial of oblimersen sodium (G3139) plus rituximab for treatment of patients with recurrent B-cell non-Hodgkin's lymphoma
2005
-
A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma
2005
-
The impact of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of anticancer agents, as perceived by patients, physicians and institution review board members (IRBs)
2005
-
Use of venous access devices in patients younger than 21 years of age
2005
-
Final analysis of a randomized phase I study of the C-RAF kinase inhibitor BAY 43-9006 in patients with acute myeloid leukemia
2004
-
Predictors of high quality clinical practice guidelines in oncology
2004
-
Zoledronic acid reduces the risk of skeletal complications in patients with malignant bone disease: evidence from 3 different multiple event analysis models
2004
-
Zoledronic acid reduces the survival-adjusted cumulative incidence of radiotherapy to bone in patients with bone metastases from breast or prostate cancer
2004
-
Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC).
2000
-
Phase III study of zoledronic acid versus pamidronate in patients with metastatic bone lesions due to breast cancer or multiple myeloma: Preliminary results.
2000
-
Phase I trial of the bombesin receptor antagonist RC-3095 in patients with refractory solid tumors
1998
-
Phase I trial of the bombesin receptor antagonist RC-3095 in patients with refractory solid tumors
1998
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)